Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

LNTH vs EXAS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.61B
5Y Perf.+527.5%
EXAS
Exact Sciences Corporation

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$20.02B
5Y Perf.+20.4%

LNTH vs EXAS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LNTH logoLNTH
EXAS logoEXAS
IndustryDrug Manufacturers - Specialty & GenericMedical - Diagnostics & Research
Market Cap$5.61B$20.02B
Revenue (TTM)$1.54B$3.25B
Net Income (TTM)$234M$-208M
Gross Margin61.1%69.7%
Operating Margin20.2%-6.4%
Forward P/E16.6x582.8x
Total Debt$738K$2.52B
Cash & Equiv.$359M$956M

LNTH vs EXASLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LNTH
EXAS
StockMay 20May 26Return
Lantheus Holdings, … (LNTH)100627.5+527.5%
Exact Sciences Corp… (EXAS)100120.4+20.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: LNTH vs EXAS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LNTH and EXAS are tied at the top with 3 categories each — the right choice depends on your priorities. Exact Sciences Corporation is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.

  • 40.0% 10Y total return vs EXAS's 16.7%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
  • Lower P/E (16.6x vs 582.8x)
Best for: long-term compounding and sleep-well-at-night
EXAS
Exact Sciences Corporation
The Income Pick

EXAS is the clearest fit if your priority is income & stability and growth exposure.

  • beta 0.12
  • Rev growth 17.7%, EPS growth 80.3%, 3Y rev CAGR 15.9%
  • Beta 0.12, current ratio 2.43x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthEXAS logoEXAS17.7% revenue growth vs LNTH's 0.5%
ValueLNTH logoLNTHLower P/E (16.6x vs 582.8x)
Quality / MarginsLNTH logoLNTH15.2% margin vs EXAS's -6.4%
Stability / SafetyEXAS logoEXASBeta 0.12 vs LNTH's 0.47
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)EXAS logoEXAS+94.3% vs LNTH's -17.8%
Efficiency (ROA)LNTH logoLNTH10.8% ROA vs EXAS's -3.5%, ROIC 30.6% vs -3.6%

LNTH vs EXAS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
EXASExact Sciences Corporation
FY 2025
Screening
77.9%$2.5B
Precision Oncology
22.1%$717M

LNTH vs EXAS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGEXAS

Income & Cash Flow (Last 12 Months)

LNTH leads this category, winning 4 of 6 comparable metrics.

EXAS is the larger business by revenue, generating $3.2B annually — 2.1x LNTH's $1.5B. LNTH is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to EXAS's -6.4%. On growth, EXAS holds the edge at +23.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLNTH logoLNTHLantheus Holdings…EXAS logoEXASExact Sciences Co…
RevenueTrailing 12 months$1.5B$3.2B
EBITDAEarnings before interest/tax$381M-$41M
Net IncomeAfter-tax profit$234M-$208M
Free Cash FlowCash after capex$349M$357M
Gross MarginGross profit ÷ Revenue+61.1%+69.7%
Operating MarginEBIT ÷ Revenue+20.2%-6.4%
Net MarginNet income ÷ Revenue+15.2%-6.4%
FCF MarginFCF ÷ Revenue+22.6%+11.0%
Rev. Growth (YoY)Latest quarter vs prior year+4.0%+23.1%
EPS Growth (YoY)Latest quarter vs prior year+5.8%+90.4%
LNTH leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

LNTH leads this category, winning 4 of 5 comparable metrics.
MetricLNTH logoLNTHLantheus Holdings…EXAS logoEXASExact Sciences Co…
Market CapShares × price$5.6B$20.0B
Enterprise ValueMkt cap + debt − cash$5.3B$21.6B
Trailing P/EPrice ÷ TTM EPS25.26x-95.37x
Forward P/EPrice ÷ next-FY EPS est.16.59x582.83x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple13.78x
Price / SalesMarket cap ÷ Revenue3.64x6.16x
Price / BookPrice ÷ Book value/share5.41x8.24x
Price / FCFMarket cap ÷ FCF15.84x56.10x
LNTH leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 8 of 9 comparable metrics.

LNTH delivers a 20.6% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-9 for EXAS. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), EXAS scores 7/9 vs LNTH's 5/9, reflecting strong financial health.

MetricLNTH logoLNTHLantheus Holdings…EXAS logoEXASExact Sciences Co…
ROE (TTM)Return on equity+20.6%-8.7%
ROA (TTM)Return on assets+10.8%-3.5%
ROICReturn on invested capital+30.6%-3.6%
ROCEReturn on capital employed+17.1%-4.0%
Piotroski ScoreFundamental quality 0–957
Debt / EquityFinancial leverage0.00x1.05x
Net DebtTotal debt minus cash-$358M$1.6B
Cash & Equiv.Liquid assets$359M$956M
Total DebtShort + long-term debt$738,000$2.5B
Interest CoverageEBIT ÷ Interest expense16.89x-5.47x
LNTH leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — LNTH and EXAS each lead in 3 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $39,000 today (with dividends reinvested), compared to $9,713 for EXAS. Over the past 12 months, EXAS leads with a +94.3% total return vs LNTH's -17.8%. The 3-year compound annual growth rate (CAGR) favors EXAS at 15.2% vs LNTH's -3.1% — a key indicator of consistent wealth creation.

MetricLNTH logoLNTHLantheus Holdings…EXAS logoEXASExact Sciences Co…
YTD ReturnYear-to-date+28.1%+3.1%
1-Year ReturnPast 12 months-17.8%+94.3%
3-Year ReturnCumulative with dividends-9.1%+53.0%
5-Year ReturnCumulative with dividends+290.0%-2.9%
10-Year ReturnCumulative with dividends+4002.4%+1672.1%
CAGR (3Y)Annualised 3-year return-3.1%+15.2%
Evenly matched — LNTH and EXAS each lead in 3 of 6 comparable metrics.

Risk & Volatility

EXAS leads this category, winning 2 of 2 comparable metrics.

EXAS is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than LNTH's 0.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs LNTH's 79.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLNTH logoLNTHLantheus Holdings…EXAS logoEXASExact Sciences Co…
Beta (5Y)Sensitivity to S&P 5000.47x0.12x
52-Week HighHighest price in past year$108.91$104.98
52-Week LowLowest price in past year$47.25$38.81
% of 52W HighCurrent price vs 52-week peak+79.1%+99.9%
RSI (14)Momentum oscillator 0–10060.576.4
Avg Volume (50D)Average daily shares traded878K4.1M
EXAS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates LNTH as "Buy" and EXAS as "Buy". Consensus price targets imply 17.2% upside for LNTH (target: $101) vs -1.6% for EXAS (target: $103).

MetricLNTH logoLNTHLantheus Holdings…EXAS logoEXASExact Sciences Co…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$101.00$103.18
# AnalystsCovering analysts1741
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+5.3%+0.1%
Insufficient data to determine a leader in this category.
Key Takeaway

LNTH leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). EXAS leads in 1 (Risk & Volatility). 1 tied.

Best OverallLantheus Holdings, Inc. (LNTH)Leads 3 of 6 categories
Loading custom metrics...

LNTH vs EXAS: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is LNTH or EXAS a better buy right now?

For growth investors, Exact Sciences Corporation (EXAS) is the stronger pick with 17.

7% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 25. 3x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LNTH or EXAS?

On forward P/E, Lantheus Holdings, Inc.

is actually cheaper at 16. 6x.

03

Which is the better long-term investment — LNTH or EXAS?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +290. 0%, compared to -2. 9% for Exact Sciences Corporation (EXAS). Over 10 years, the gap is even starker: LNTH returned +40. 0% versus EXAS's +1672%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LNTH or EXAS?

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Lantheus Holdings, Inc. 's 0. 47β — meaning LNTH is approximately 290% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — LNTH or EXAS?

By revenue growth (latest reported year), Exact Sciences Corporation (EXAS) is pulling ahead at 17.

7% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LNTH or EXAS?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -6. 4% for Exact Sciences Corporation — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -6. 4% for EXAS. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LNTH or EXAS more undervalued right now?

On forward earnings alone, Lantheus Holdings, Inc.

(LNTH) trades at 16. 6x forward P/E versus 582. 8x for Exact Sciences Corporation — 566. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LNTH: 17. 2% to $101. 00.

08

Which pays a better dividend — LNTH or EXAS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is LNTH or EXAS better for a retirement portfolio?

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1672% 10Y return). Both have compounded well over 10 years (EXAS: +1672%, LNTH: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LNTH and EXAS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LNTH is a small-cap quality compounder stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 9%
Run This Screen
Stocks Like

EXAS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 41%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LNTH and EXAS on the metrics below

Revenue Growth>
%
(LNTH: 4.0% · EXAS: 23.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.